Launch of new medical device to fight STIs slated for early 2019
DORAL, Florida, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTCQB: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces the production of the first commercial production run of Hygee™, its new, original medical device to fight sexually transmitted infections (STIs). The official launch is scheduled for early 2019.
After numerous partnerships, tests, distribution agreements and prepping, ETST has officially ordered a first production run of Hygee™. Initial marketing will target North America, South America, Asia and Africa, and the Company will package Hygee™ in English, French, Portuguese, Spanish, Vietnamese and Arabic to reach an wide audience of consumers. These languages are mother tongues for 1.5 billion people, with many other ethnic groups using English as a second language. By offering Hygee™ in different languages, ETST can reach the majority of individuals globally, as well as those in the Company’s current agreed distribution network, shared in November.
The Hygee™ self-sampling kit includes a discreet, wearable medical device that enables a woman to anonymously test for STIs such as chlamydia. Testing for this disease is particularly important for pregnant women, who must be screened for chlamydia infections to minimize the risk of transmission of the infection to their babies during childbirth. In any given year, approximately 8 million women give birth in the United States, Canada, Brazil, Mexico, Morocco, Djibouti, and Vietnam where Hygee™ will first be offered.
While this niche represents a considerable market for the Hygee™ medical device, opportunity exists well beyond pregnant women. The World Health Organization recommends that all sexually active women aged 15 to 25 get tested yearly for chlamydia, representing a market of about 500 million women worldwide.
Dr. Michel Aube, ETST’s CEO and chief science officer, states, “No other existing method of collecting genital specimens from women is more convenient or more efficient than Hygee™. Through intentional design, Hygee™ is a ‘mistake proof’ medical device with extremely simple instructions that allow any woman, regardless of age or education the assurance of correctly using the kit on the first try. With roughly 130 million new chlamydia cases diagnosed yearly, according to the WHO, Hygee™ is dedicated to this area of women’s health.”
ETST’s projections for Hygee™ anticipate strong sales growth in years two and three after product launch. As soon as year one, sales of Hygee™ and the associated in vitro molecular diagnoses should reach between $1.5 million and $2.5 million USD. Second year sales should reach $1 million monthly and up to $20 million yearly as early as the third year. These numbers are supported by the fact that chlamydia is a global issue; that the company’s network of distributors is worldwide; and that the thin structure of the device and the stability of the specimen collected with Hygee™ ensures that it can be easily dispersed on all continents.
“We believe that ETST has developed the best tool on the market to fight STIs, which will provide an exceptional service to women who use Hygee™,” states Nickolas S. Tabraue, the company’s president, director, and chairman. “The production of the first batch of Hygee™ is very exciting. Our team believed in the success of Hygee™ from the first day we acquired it. Now, we will do everything possible to spread this fabulous medical device everywhere on the planet to protect women and their future babies from the terrible, adverse effects of chlamydia and other STIs.”
About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, in addition to studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit: www.EarthScienceTech.com
ETST currently has four wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors:
Earth Science Pharmaceutical, Inc.
Earth Science Pharmaceutical ("ESP") is a wholly-owned subsidiary of Earth Science Tech, committed to the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP's CEO and chief science officer, Dr. Michel Aubé, is leading the Company’s research and development efforts. The Company’s first medical device, Hygee™, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women. To learn more please visit: www.EarthSciencePharmaceutical.com
Cannabis Therapeutics, Inc.
Cannabis Therapeutics (“CTI”) is a wholly-owned subsidiary of Earth Science Tech, Inc. poised to take a leadership role in the development of new, leading-edge cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs. To learn more please visit: www.CannabisThera.com
KannaBidioiD (“KBD”) is a wholly-owned subsidiary of Earth Science Tech, Inc. that provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy. To learn more please visit: www.KannaBidioiDInc.com
Earth Science Foundation, Inc.
Earth Science Foundation (“ESF”) is a wholly-owned subsidiary of Earth Science Tech, Inc. ESF is in the process of becoming a non-profit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech's effective CBD products to those in need. To learn more please visit: www.ETSTFoundtion.org
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, listing on the CSE, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Nickolas S. Tabraue
President, Director & Chairman